Audit: QRS - Lactobacillus reuteri for Health & Longevity

Audit conducted on 05/09/2026 06:17 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Dose ladder, strain-to-goal mapping, timing, tier lists, gates, 8 markers, cadence and 6 qualitative items all trace to ER lines 271–486.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No empty-state or hedging phrasing in the ER was altered; conflicted findings remain in the tier the ER assigned.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication list preserves the ER’s absolute framing; benefits stay in their ER tiers.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; the immune-suppressant bullet the ER labels “Absolute contraindication” is placed under Contraindications, not Key Interactions.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names appear; strain designations (NCIMB 30242, DSM 17938, ATCC PTA 5289, ATCC PTA 6475) are verbatim from ER line 380.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same sober, strain-specific, conflict-of-interest-aware register as the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Targets and cadence give the reader something to act on without overselling.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Declarative throughout; no prescriptions issued.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Protocol and monitoring cells describe what trials did and what ranges are used, not what to do.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised”, “should” anywhere in the populated spans.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present (verified by scan).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are decision-bearing marker and contraindication names carried over from the ER; At-A-Glance is fully plain.
2.8	Information is presented in a concise and very compact manner	🟢	Every populated span is a condensed clause or fragment.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; no “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Strain-matching, biomarker targets and rescan intervals presuppose a self-tracking reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	12-month bone dosing, night-time lozenge, two-hour antibiotic separation implied without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes lipid panels, apoB, DXA and urea breath testing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance names the funding problem and the animal-only basis of the popular claims.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“longevity-oriented trial” in marker_5_why; “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Terminology is the ER’s own (“D-lactic acidosis”, “peri-implant pocket depth”, “brain fogginess” is the ER’s section heading).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Diff against [qrs_template] shows every fixed heading, gate title, tier label and column header byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template spans present; the only additions are repeated marker_#/qualitative_item_# rows, which the template defines as repeatable.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff confirms only checklist-addressed variables were populated; CSS, structure and the website= spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label are “Standard maintenance dose”, “Strain matched to goal”, “Best time of day” — verbatim ER bold labels (ER lines 378, 380, 386); all 8 marker names verbatim from the ER monitoring table.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol cell labels and monitoring row labels are exact; time-to-effect labels use the ER’s own phrases (“cholesterol effect”, “bone signal”, ER line 433).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Scan returned no emoji characters; the ER’s ⚠️ Conflicted flags were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to fragments; item counts are the minimum permitted by items 9.2, 12.2, 13.2, 14.2 and 15.2, and no section carries prose beyond the key fact.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” line 3, closing “—” line 13; the title text on line 2 precedes it.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no value is echoed except through the header spans that item 6 requires.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: lactobacillus_reuteri_2026-0905-0253_Opus_ER.md (line 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0905-0535.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no context-window or other qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: lactobacillus_reuteri_2026-0905-0253_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified; all values clean, git_user and git_issue unquoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Lactobacillus reuteri for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Lactobacillus reuteri for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0905-0535 → “09/05/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template’s subline; the ER’s “Also known as” line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 507–509: strain-not-species, the two firm findings, the conflicted domains, the animal-only claims, and the funding caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words (counted programmatically).
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the five clauses maps to a distinct sentence in the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“artery-clogging cholesterol” for LDL, “the drug course against a common stomach infection” for H. pylori eradication; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers to “the cholesterol and workplace trials” generically, with no name, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to ER lines 335 and 349–356.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six “Populations who should avoid” bullets plus the ER’s one absolute contraindication (immune suppressants/chemotherapy during profound neutropenia).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements, lines 542–548.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes, rationale or citations; the ER’s plain-language glosses were stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(below 500 cells/µL)”, “within 6 months of anti-rejection therapy”, “during profound neutropenia” and “(tacrolimus)” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations plus one absolute contraindication, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items trace to ER lines 329–347.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the ER’s ten interaction bullets; the immune-suppressant/chemotherapy bullet is correctly excluded because it sits under Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements, lines 556–564.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a drug class plus an example; the ER’s Caution/Monitor verdicts and mechanistic sentences are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every item retains at least one named example drug or exposure; longer ER lists are trimmed, never dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists ten interactions, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol lines 378, 380 and 386.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, strain selection and timing — the three levers the ER’s own protocol opens with and the only ones that change what a reader buys and when they take it.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER’s protocol carries twelve bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; the dose ladder, strain-to-endpoint map and meal timing are ER-sourced.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER names exactly three windows (line 433): digestive 1–4 weeks, cholesterol 6–9 weeks, bone 12 months; all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Cholesterol (ER High tier) → bowel/digestive change (Medium) → bone (Low), matching the ER’s own benefit tiers.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; the sub-lines draw on ER lines 271, 433 and 465.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 433), so the row is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All fifteen entries map one-to-one to the ER’s benefit sub-headings, lines 155–243.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Entries are bare noun phrases; the ER’s Magnitude figures and ⚠️ Conflicted flags are excluded.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER tiers contain benefits, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight entries map one-to-one to the ER’s risk sub-headings, lines 267–309.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Entries are bare noun phrases; the relative risk of 3.67 and the D-lactic acidosis percentages are excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER tiers contain risks, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows correspond to the ER biomarker table, lines 467–476.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers present, with targets and rationale carried over faithfully.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 12-week panel, 6-to-12-month interval and 12-to-24-month bone rescan, condensed from ER lines 463–465.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items map to the ER’s “Qualitative markers tracked alongside the laboratory values” list, lines 478–485.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, in the ER’s own order.

Issues 05/09/2026 06:17

Pass rate 100.00%. No issues found.

Issues 05/09/2026 06:04

1. 1.1 / 1.3 — Eradication claim strengthened: [action_2_sub] at line 461 reads “DSM 17938 for constipation and eradication”, dropping the ER’s qualifier from “DSM 17938 alone for constipation and eradication support” (ER line 380); the ER states the species “does not clear infection on its own” (ER line 193), so the shortened wording overstates the strain’s role.

Fixes 05/09/2026 06:04

1. 1.1 / 1.3 — Eradication claim restored to ER wording: [action_2_sub] changed from “DSM 17938 for constipation and eradication” to “DSM 17938 alone for constipation and eradication support”, matching the ER Protocol bullet and preserving the distinction between supporting a regimen and clearing the infection.

Issues 05/09/2026 06:01

1. 7.4 — Research-register word in At-A-Glance: Line 433 closes with “company-funded and unreplicated”; “unreplicated” is methodology register a non-specialist would not use unprompted, whereas the ER states it plainly as “independent replication has not followed”.

Fixes 05/09/2026 06:01

1. 7.4 — Research-register word in At-A-Glance: Replaced “company-funded and unreplicated” with “company-funded and never independently repeated” in [at_a_glance], matching the ER’s own plain phrasing; the paragraph remains within the 60-word limit.

Issues 05/09/2026 05:51

1. 4.5 — Sheet exceeds one A4 page: Key Interactions (lines 556-564), Contraindications (lines 542-548), Benefits “Low” (line 528) and the six Protocol/Time-to-effect sub cells (lines 450, 461, 472, 489, 500, 511) carry near-verbatim ER prose rather than condensed content, so the sheet renders well past a single A4 page.

Fixes 05/09/2026 05:51

1. 4.5 — Gate items condensed: Trimmed both decision gates to fit the one-page budget — Contraindications shortened (“neutrophil count below 500 cells/µL” → “below 500 cells/µL”, “documented D-lactic acidosis” → “D-lactic acidosis”) and Key Interactions reduced to a single named example drug per class, with every parenthetical retained.

2. 4.5 — Benefits and Risks tiers tightened: Removed redundant qualifiers from the Medium, Low and Speculative benefit items and from the Speculative risk item (e.g. “fewer days of sick leave from respiratory and digestive infections” → “fewer sick-leave days from infections”), keeping every ER heading represented.

3. 4.5 — Protocol and Time-to-effect subs shortened: Replaced the near-verbatim ER sentences in all six sub cells with compact equivalents (e.g. “For oral endpoints the lozenge dissolves at night after brushing, maximizing contact time.” → “Oral-endpoint lozenges dissolve at night after brushing.”).

4. 4.5 — Monitoring and Qualitative wording compressed: Shortened four Monitoring target/why cells and three Qualitative items (e.g. “below 70 mg/dL where artery plaque is known” → “below 70 mg/dL with known plaque”), leaving all eight markers and all six qualitative items in place.

Issues 05/09/2026 05:37

1. 4.5 — Content overflows one A4 page: The QRS carries ER content over near-verbatim instead of condensing it, and at 11pt on A4 the sheet runs to roughly two pages; the heaviest contributors are the nine Key Interactions with full four-drug example lists (lines 555–565), the eight Monitoring “Target”/”Why” cells copied whole from the ER table (lines 603–691), and the over-long action_2_sub (line 461) and time_1_sub (line 489).

Fixes 05/09/2026 05:37

1. 4.5 — Key Interactions example lists trimmed: Shortened the parenthetical drug lists to two examples each and dropped the “prescription and over-the-counter” and “Over-the-counter” elaborations; no interaction bullet was removed.
2. 4.5 — Contraindications tightened: Condensed three stop items, e.g. “Profound neutropenia (absolute neutrophil count below 500 cells/µL) or blood cancer under active treatment” to “Profound neutropenia (neutrophil count below 500 cells/µL) or blood cancer under treatment”, keeping every threshold and time window.
3. 4.5 — Monitoring cells condensed: Shortened six “Target”/”Why” cells (e.g. marker_1_why from “The primary endpoint of the two positive adult trials” to “Primary endpoint of the two positive adult trials”) and compressed monitoring_cadence from 200 to 149 characters; all eight biomarker rows retained.
4. 4.5 — Protocol and time-to-effect subs shortened: Trimmed action_2_sub and action_3_sub, and cut time_1_sub from “Lipid panel, high-sensitivity C-reactive protein and vitamin D are repeated at 12 weeks, which covers this window.” to “Lipid panel, hs-CRP and vitamin D repeat at 12 weeks, covering this window.”
5. 4.5 — At-A-Glance tightened: Merged two sentences and replaced “without independent replication” with “unreplicated”, reducing the paragraph from 433 to 405 characters while staying within the 60-word limit.